期刊
JAMA PSYCHIATRY
卷 74, 期 4, 页码 399-405出版社
AMER MEDICAL ASSOC
DOI: 10.1001/jamapsychiatry.2017.0080
关键词
-
类别
资金
- Allergan
- Alkermes
- AstraZeneca
- BioHaven Pharmaceuticals
- Hoffman La-Roche
- Johnson & Johnson (Janssen)
- Merck
- Naurex
- Servier Pharmaceuticals
- Taisho Pharmaceuticals
- Teva
- Vistagen Therapeutics
- Sanofi
- AssureRx
- Janssen Research Development
- Mayo Foundation
- Myriad Genetics
- Pfizer
- Mayo
- Janssen Research & Development LLC
- Mitsubishi Tanabe Pharma Corporation
- Neuralstem Inc
- Sunovion
- Supernus Pharmaceuticals
- Teva Pharmaceuticals
- National Institute of Mental Health
- National Institute of Neurological Disease and Stroke
- Stanley Foundation
- Soterix
- Neuronetics
- Cervel Neurotherapeutics
- Department of Veterans Affairs
- Otsuka
- Acadia
- Cerecor
- Genentech
- Valeant
- Johnson Family Chair for Research in Psychiatry at Baylor College of Medicine
- Forum
- Gilead
- Takeda
- Xhale
- Clintara
IMPORTANCE Several studies now provide evidence of ketamine hydrochloride's ability to produce rapid and robust antidepressant effects in patients with mood and anxiety disorders that were previously resistant to treatment. Despite the relatively small sample sizes, lack of longer-term data on efficacy, and limited data on safety provided by these studies, they have led to increased use of ketamine as an off-label treatment for mood and other psychiatric disorders. OBSERVATIONS This review and consensus statement provides a general overview of the data on the use of ketamine for the treatment of mood disorders and highlights the limitations of the existing knowledge. While ketamine may be beneficial to some patients with mood disorders, it is important to consider the limitations of the available data and the potential risk associated with the drug when considering the treatment option. CONCLUSIONS AND RELEVANCE The suggestions provided are intended to facilitate clinical decision making and encourage an evidence-based approach to using ketamine in the treatment of psychiatric disorders considering the limited information that is currently available. This article provides information on potentially important issues related to the off-label treatment approach that should be considered to help ensure patient safety.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据